Piper Jaffray Fulgent Genetics Prices $26.2M Public Stock Offering The genetic testing firm is offering approximately 2.3 million shares at $11.25 per share and plans to use the funds for general corporate purposes. Pacific Biosciences Stock Upgraded by Piper Jaffray The bank believes investors are too focused on the potential of PacBio's merger with Illumina falling through rather than recent developments regarding its technology. Fulgent Genetics to Offer $22.5M in Stock The genetic testing firm has entered into an equity distribution agreement with Piper Jaffray to offer up to $30 million in stocks, with an initial offering of $22.5 million. Genomic Health Upgraded to Overweight by Piper Jaffray The investment bank cited management confidence in US and European test growth as meriting the upgrade, which was necessary to maintain a current $72 price target on the firm's stock. Piper Jaffray Initiates Coverage of OncoCyte With Overweight Rating An analyst said the DetermaVu test could potentially be best in class for lung cancer diagnosis and that CMS could begin reimbursing for it in late 2020. Oct 10, 2018 Myriad Upgraded to Overweight by Piper Jaffray; Signs Lab Service Deal with Pfizer Jul 27, 2015 Piper Jaffray Initiates Coverage of Natera with Overweight Rating Aug 11, 2014 Piper Jaffray, Mizuho Initiate Coverage of CareDx with Bullish Outlooks Jun 20, 2014 Piper Jaffray Initiates Coverage of Veracyte with Overweight Rating Dec 4, 2013 Qiagen Officials Talk TB Test, GeneReader Opportunities at Piper Jaffray Conference Sep 18, 2013 Investment Bank Upgrades BD to Overweight, Raises Price Target Sep 18, 2013 Piper Jaffray Initiates Coverage of PerkinElmer with Overweight Rating Sep 5, 2013 Piper Jaffray Upgrades BioMérieux on Plans to Buy BioFire Aug 2, 2013 Piper Jaffray Upgrades PacBio Following Earnings Results Jul 19, 2013 Piper Jaffray Upgrades Cepheid; Other Analysts More Cautious Jul 17, 2013 Piper Jaffray Downgrades Hologic, Citing Competition from Roche's HPV Business Jul 2, 2013 Piper Jaffray Downgrades Illumina Stock Mar 1, 2013 Piper Jaffray Upgrades Sequenom to Overweight Jan 4, 2013 Piper Jaffray Downgrades Cepheid on Lingering Manufacturing Issues Oct 9, 2012 Analysts, Investors 'Troubled' as Affymetrix's Preliminary Q3 Revenues Miss Estimates Premium Oct 9, 2012 Piper Jaffray Upbeat on MiSeq; Dismisses Rumors of Roche-Illumina Deal Oct 4, 2012 Piper Jaffray Initiates Coverage of Quidel with Overweight Rating, Noting Firm's MDx Shift Sep 24, 2012 Piper Jaffray Downgrades Sequenom Stock Sep 13, 2011 Piper Jaffray Initiates Coverage of Meridian Bioscience with Underweight Rating Jun 24, 2011 Piper Jaffray Raises Price Target on Cepheid Stock Load More Breaking News Lunaphore Technologies, University of Bern Partner on Colorectal Cancer Study People in the News: New Appointments at Biocept, Novacyt, Centogene, Illumina, More In Brief This Week: Sophia Genetics, Twist Bioscience, Dante Labs, MGI, Codex DNA, More New Products Posted to GenomeWeb: SpeeDx, Bio-Techne, NuProbe, More DiaSorin Q2 Revenues Rise 20 Percent on SARS-CoV-2 Testing Demand Cepheid Gets $28M From BARDA for SARS-CoV-2 Tests The Scan Interfering With Invasive Mussels The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels. Participation Analysis A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports. Right Whales' Decline A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC. Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.